Breast Cancer | Specialty

Pyrotinib Shows Early Promise in HER2+ Breast Cancer

May 23rd 2017

In phase I results from China published in the Journal of Clinical Oncology, oral pyrotinib (HTI-1001) was well-tolerated and showed antitumor activity in women with HER2-positive breast cancer.

Dr. Brufsky Discusses Resistance to HER2-Targeted Therapies

May 23rd 2017

Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses resistance to HER2-targeted therapy in breast cancer.

Expert Explains Individualized Decision on Endocrine Therapy Beyond 5 Years in Breast Cancer

May 22nd 2017

Amye J. Tevaarwerk, MD, discusses how physicians decide on extending endocrine therapy beyond 5 years for patients with ER-positive breast cancer, the tools she hopes will soon become available to help clarify this decision, and the clinical research in this population she is eagerly awaiting.

Using Ribociclib in the First-Line Setting

May 22nd 2017

First-Line Patient Selection for CDK Inhibitor Use

May 22nd 2017

Recent FDA Approval of Ribociclib as Upfront Therapy

May 22nd 2017

CDK Inhibitors in Metastatic Hormone-Driven Breast Cancer

May 22nd 2017

O'Regan Covers Scope of ER+ and HER2+ Breast Cancer Advancements

May 22nd 2017

Ruth O’Regan, MD, provides insight on the evolving landscapes of ER-positive and HER2-positive breast cancers, and what regimens remain solid approaches for effective patient outcomes.

The Hunt for Biomarkers and Better Treatments in Advanced TNBC

May 21st 2017

In an OncLive Peer Exchange® discussion, experts in breast malignancies reviewed some exciting new developments in TNBC.

Dr. Piccart Discusses Biomarkers in Early Breast Cancer

May 19th 2017

Martine J. Piccart, MD, PhD, professor, Université Libre de Bruxelles, director, Medicine Department, Institut Jules Bordet, discusses biomarkers in early breast cancer.

Dr. O'Regan Discusses the Future of Treatment in HER2+ Breast Cancer

May 16th 2017

Ruth O’Regan, MD, division head of Hematology and Oncology in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health, discusses the potential of future treatments for patients with HER2-positive breast cancer.

Dr. Burstein on Adjuvant Endocrine Therapy for ER+ Breast Cancer

May 9th 2017

Harold J. Burstein, MD, PhD, senior physician, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses adjuvant endocrine therapy for postmenopausal women with ER-positive breast cancer.

FDA Approves Co-Packaging of Ribociclib With Letrozole for Metastatic Breast Cancer

May 9th 2017

The FDA has approved co-packaging of the oral medications ribociclib (Kisqali) and letrozole (Femara) for the treatment of postmenopausal women with HR-positive, HER2-negative advanced breast cancer.

Expert Weighs In on Neratinib Ahead of FDA Panel Review

May 9th 2017

Wolfgang Janni, MD, PhD, discusses toxicity management with neratinib and other agents for HER2-positive breast cancer, as well as emerging treatments and impactful trials in the field.

Dr. Carey on De-Escalating Treatments for Triple-Negative Breast Cancer

May 8th 2017

Lisa A. Carey, MD, professor, UNC Lineberger Comprehensive Cancer Center, discusses de-escalating treatments for patients with triple-negative breast cancer (TNBC).

UVA Explores Same-Day Brachytherapy With Surgery for Early Breast Cancer

May 4th 2017

The University of Virginia Cancer Center has developed a new method for delivering radiation therapy along with less invasive surgery in a more precise and personalized manner.

Tripathy Highlights Neoadjuvant Advances in HER2+ Breast Cancer

May 3rd 2017

Debu Tripathy, MD, discusses current and emerging treatment strategies in the neoadjuvant setting for patients with HER2-postive breast cancer.

HER2+ Breast Cancer Heterogeneity Calls for Combos

May 2nd 2017

Targeted therapies have improved outcomes for HER2-positive breast cancer, which is characterized by an aggressive tumor phenotype and lower overall survival. However, questions remain on how to predict which patients will benefit from neoadjuvant or extended HER2-targeted therapies and how to treat patients with triple-positive breast cancer.

Dr. Janni on the Future of Treatments for HER2-Positive Breast Cancer

May 2nd 2017

Wolfgang Janni, MD, PhD, University of Ulm, discusses the future of treatments for patients with HER2-positive breast cancer.

Dr. Osborne on Pertuzumab in HER2+ Breast Cancer

April 25th 2017

Kent Osborne, MD, director, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses pertuzumab (Perjeta) in HER2-positive breast cancer.